Announcement under Regulation 30 (LODR)-Press Release / Media Release
We are pleased to enclose herewith our Press Release relating to US FDA Approval of INFUGEM Injection, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Advertisement published in newspapers regarding Notice for transfer of equity shares and unclaimed dividend to the Investor Education and Protection Fund (IEPF) Suspense Account Clarification Reply
Sub: Clarification to NSE We refer to your query, a copy of which is attached herewith, vide your email dated today, July 12, 2018 seeking clarification on announcement submitted by us to the Exchange dated July 11, 2018, regarding SUNPHARMA: Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated July 11, 2018, titled "DUSA Pharmaceuticals, Inc. files lawsuit against Biofrontera Inc. for patent infringement,...
Sun Pharma unit files patent case against German firm
DUSA has also alleged that the Germany-based Biofrontera improperly obtained confidential information from former employees Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to DUSA Pharmaceuticals, Inc. (a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd.) filing a lawsuit against Biofrontera Inc. in USA for patent infringement, trade secret misappropriation, and tortious interference, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma signs Akshay Kumar as Revital H Brand Ambassador. Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Family Investment Pvt Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Pratham Investments Sun Pharma nears 52-week high as stock surges 32% in five weeks
The stock was trading 2% higher at Rs 587 on the BSE in otherwise subdued market, trading nears to 52-week high of Rs 609 touched on February 12, 2018. Sun Pharma sharpens R&D; for efficiencies with digital applications
The drug maker has guided for an increase in R&D expenses in FY 19 as it builds a pipeline of specialty products